share_log

Skye Bioscience Signs Arrangement Agreement With Emerald Health Therapeutics, Here Are The Details

Benzinga Real-time News ·  May 13, 2022 00:23

Skye Bioscience, Inc.(OTCQB:SKYE)and Emerald Health Therapeutics, Inc. (OTCQB:EMHTF) (CSE:EMH)have entered into a definitive agreementwith respect to a transaction to be completed by way of a plan of arrangementwhereby Skye would acquire all of the issued and outstanding shares of Emeraldin a share-for-share-transaction.

Skye is a San Diego-based pharmaceutical companydeveloping proprietary, synthetic cannabinoid derivatives to treat glaucoma and other diseases with significant unmet needs. Emerald possesses cash and non-cash assets that Skye would acquire through the arrangement. The proposed arrangement is subject to approval by each...

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment